At CyberKnife Center of Chicago, we’re dedicated to contributing and learning about the latest in cancer research for stereotactic body radiation therapy (SBRT). In addition to its recent categorization as a primary treatment option for prostate cancer, physicians around the world are also working to expand the treatment method’s applications. Read more about the latest in SBRT treatment:
In an observational study by the University of Washington in Seattle, researchers found data that indicated potential for improved survival rates for patients with brain metastases who received stereotactic radiosurgery (SRS). The study compared SRS to whole-brain radiation therapy (WBRT) in 413 patients who were diagnosed with non-small cell lung cancer and with fewer than four brain metastases. Researchers found that those treated with SRS had an overall survival of nine months compared to 3.9 months for patients treated with WBRT. The findings suggest that improved survival rates could be among the benefits that SRS offers to patients diagnosed with the disease.
This is not intended as medical advice to replace the expertise and judgment of your health care team. It is intended to help you and your family make informed decisions, together with your doctor.